Taysha Gene Therapies, Inc. (TSHA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 1 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

9
Taysha Gene Therapies (TSHA) Q2 2026: $230M Capital Raise Extends Cash Runway Into 2H 2028 Amid Pivotal Trial Completion
August 12, 2026
9
Taysha (TSHA) Q1 2026: R&D Spend Climbs 116% as BLA Submission Nears for Rett Gene Therapy
May 06, 2026
7
Taysha (TSHA) Q4 2025: $20M R&D Surge Accelerates TASHA-102 Pivotal Pathway
March 19, 2026
8
Taysha Gene Therapies (TSHA) Q3 2025: Breakthrough Designation Secured as 100% Response Rate Achieved in High-Dose Cohort
November 04, 2025
10
Taysha (TSHA) Q2 2025: $230M Raise Extends Runway, Pivotal Rett Trial Site Activation Signals Regulatory Momentum
August 12, 2025
8
Taysha (TSHA) Q1 2025: FDA Alignment Accelerates Pivotal Trial Pathway for Rett Gene Therapy
July 07, 2025

Browse all companies